Kazuki Kumada

Kazuki Kumada

Auto-generated profile, based on publicly available information

Kazuki Kumada

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Toxins
Verified
Journal Article
Open access
PDF file
EHEiji Hishinuma
Eiji Hishinuma
MSMuneaki Shimada
Muneaki Shimada
NMNaomi Matsukawa
Naomi Matsukawa
DSDaisuke Saigusa
Daisuke Saigusa
BLBin Li
Bin Li
NYNobuo Yaegashi
Nobuo Yaegashi
Epithelial ovarian cancer (EOC) is a fatal gynecologic cancer, and its poor prognosis is mainly due to delayed diagnosis. Therefore, biomarker identification and prognosis prediction are crucial in EOC. Altered cell metabolism is a characteristic feature of cancers, and metabolomics reflects an individual’s current phenotype. In particular, plasma metabolome analyses can be useful for biomarker identification. In this study, we analyzed 624 metabolites, including uremic toxins (UTx) in plasma derived from 80 patients with EOC using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Compared with the healthy control, we detected 77 significantly increased metabolites and 114 significantly decreased metabolites in EOC patients. Especially, decreased concentrations of lysophosphatidylcholines and phosphatidylcholines and increased concentrations of triglycerides were observed, indicating a metabolic profile characteristic of EOC patients. After calculating the parameters of each metabolic index, we found that higher ratios of kynurenine to tryptophan correlates with worse prognosis in EOC patients. Kynurenine, one of the UTx, can affect the prognosis of EOC. Our results demonstrated that plasma metabolome analysis is useful not only for the diagnosis of EOC, but also for predicting prognosis with the variation of UTx and evaluating response to chemotherapy.

24 January 2024 in The Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
YAYu-Ichi Aoki
Yu-Ichi Aoki
KTKeiko Taguchi
Keiko Taguchi
HAHayato Anzawa
Hayato Anzawa
JKJunko Kawashima
Junko Kawashima
NINoriko Ishida
Noriko Ishida
MYMasayuki Yamamoto
Masayuki Yamamoto
Whole blood transcriptome analysis is a valuable approach in medical research, primarily due to the ease of sample collection and the richness of the information obtained. Since the expression profile of individual genes in the analysis is influenced by medical traits and demographic attributes such as age and gender, there has been a growing demand for a comprehensive database for blood transcriptome analysis. Here, we performed whole blood RNA sequencing (RNA-seq) analysis on 576 participants stratified by age (20-30s and 60-70s) and gender from cohorts of the Tohoku Medical Megabank (TMM). A part of female segment included pregnant women. We did not exclude the globin gene family in our RNA-seq study, which enabled us to identify instances of hereditary persistence of fetal hemoglobin based on the HBG1 and HBG2 expression information. Comparing stratified populations allowed us to identify groups of genes associated with age-related changes and gender differences. We also found that the immune response status, particularly measured by neutrophil-to-lymphocyte ratio (NLR), strongly influences the diversity of individual gene expression profiles in whole blood transcriptome analysis. This stratification has resulted in a dataset that will be highly beneficial for future whole blood transcriptome analysis in the Japanese population.

24 July 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
JYJun Yasuda
Jun Yasuda
FKFumiki Katsuoka
Fumiki Katsuoka
IDInaho Danjoh
Inaho Danjoh
YKYosuke Kawai
Yosuke Kawai
KKKaname Kojima
Kaname Kojima
MYMasayuki Yamamoto
Masayuki Yamamoto
Genotype imputation from single-nucleotide polymorphism (SNP) genotype data using a haplotype reference panel consisting of thousands of unrelated individuals from populations of interest can help to identify strongly associated variants in genome-wide association studies. The Tohoku Medical Megabank (TMM) project was established to support the development of precision medicine, together with the whole-genome sequencing of 1070 human genomes from individuals in the Miyagi region (Northeast Japan) and the construction of the 1070 Japanese genome reference panel (1KJPN). Here, we investigated the performance of 1KJPN for genotype imputation of Japanese samples not included in the TMM project and compared it with other population reference panels. We found that the 1KJPN population was more similar to other Japanese populations, Nagahama (south-central Japan) and Aki (Shikoku Island), than to East Asian populations in the 1000 Genomes Project other than JPT, suggesting that the large-scale collection (more than 1000) of Japanese genomes from the Miyagi region covered many of the genetic variations of Japanese in mainland Japan. Moreover, 1KJPN outperformed the phase 3 reference panel of the 1000 Genomes Project (1KGPp3) for Japanese samples, and IKJPN showed similar imputation rates for the TMM and other Japanese samples for SNPs with minor allele frequencies (MAFs) higher than 1%. 1KJPN covered most of the variants found in the samples from areas of the Japanese mainland outside the Miyagi region, implying 1KJPN is representative of the Japanese population’s genomes. 1KJPN and successive reference panels are useful genome reference panels for the mainland Japanese population. Importantly, the addition of whole genome sequences not included in the 1KJPN panel improved imputation efficiencies for SNPs with MAFs under 1% for samples from most regions of the Japanese archipelago.

18 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANAyako Nishizawa
Ayako Nishizawa
KKKazuki Kumada
Kazuki Kumada
KTKeiko Tateno
Keiko Tateno
MWMaiko Wagata
Maiko Wagata
SSSakae Saito
Sakae Saito
JSJunichi Sugawara
Junichi Sugawara
Preeclampsia is a pregnancy-induced disorder that is characterized by hypertension and is a leading cause of perinatal and maternal–fetal morbidity and mortality. HLA-G is thought to play important roles in maternal–fetal immune tolerance, and the associations between HLA-G gene polymorphisms and the onset of pregnancy-related diseases have been explored extensively. Because contiguous genomic sequencing is difficult, the association between the HLA-G genotype and preeclampsia onset is controversial. In this study, genomic sequences of the HLA-G region (5.2 kb) from 31 pairs of mother–offspring genomic DNA samples (18 pairs from normal pregnancies/births and 13 from preeclampsia births) were obtained by single-molecule real-time sequencing using the PacBio RS II platform. The HLA-G alleles identified in our cohort matched seven known HLA-G alleles, but we also identified two new HLA-G alleles at the fourth-field resolution and compared them with nucleotide sequences from a public database that consisted of coding sequences that cover the 3.1-kb HLA-G gene span. Intriguingly, a potential association between preeclampsia onset and the poly T stretch within the downstream region of the HLA-G*01:01:01:01 allele was found. Our study suggests that long-read sequencing of HLA-G will provide clues for characterizing HLA-G variants that are involved in the pathophysiology of preeclampsia.

1 September 2025 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
LBLiam Baird
Liam Baird
LZLin Zhang
Lin Zhang
THTakanori Hidaka
Takanori Hidaka
LXLyu Xi
Lyu Xi
KWKe Wang
Ke Wang
MYMasayuki Yamamoto
Masayuki Yamamoto
Background: The development and clinical success of KRAS G12C inhibitors was a landmark achievement in anti-cancer drug development, as oncogenic KRAS had long been considered an intractable therapeutic target. Patients with KRAS mutant lung cancers frequently present with co-mutations in the KEAP1-NRF2 pathway, and because genetic activation of NRF2 results in resistance to all current anti-cancer therapies, we were motivated to explore how aberrant activation of NRF2 impacts the clinical response to KRAS G12C inhibitors. Methods: A broad range of techniques, including genetic knockouts, scRNA-seq and surface plasmon resonance, were used to determine the effect of KRAS G12C drugs on NRF2. Results: At physiologically-relevant concentrations, both of the clinically-approved KRAS G12C inhibitors Sotorasib and Adagrasib also function as inducers of NRF2. Mechanistically, the same cysteine-targeting functionality which allows these electrophilic drugs to inhibit the mutant KRAS G12C protein also facilitates their binding to cysteine-based sensors in KEAP1, resulting in the upregulation of the NRF2-dependent gene expression program. Conclusions: The activation of NRF2 by KRAS-G12C inhibitors represents a unique example of anti-cancer drugs which positively regulate the activity of a protein which is normally considered to be an oncogene. In both the malignant cells of the tumour and immune cells within the microenvironment, activation of NRF2 by electrophilic KRAS inhibitors positively contributes to the clinical efficacy of these drugs by promoting anti-cancer immunity. This unprecedented situation, in which the NRF2-dependent oxidative stress response is induced globally within cancer patients, has a number of important clinical implications, particularly in relation to ongoing combination chemotherapy clinical trials, as well as for selecting patient populations which may derive the most benefit from G12Ci anti-cancer drugs.

10 April 2025 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
TATakafumi Akimoto
Takafumi Akimoto
HIHiroshi Inaba
Hiroshi Inaba
SOSoichi Ogishima
Soichi Ogishima
KKKazuki Kumada
Kazuki Kumada
AMAyano Mitsuhashi
Ayano Mitsuhashi
EKEi Kinai
Ei Kinai
• Analysis of the Japanese genome database showed no firm association between VWF pathogenic variants and phenotypic expression. • Estimating VWD prevalence directly based on the variant allele frequencies risks overestimation.